Clenbuterol
( DrugBank: Clenbuterol / KEGG DRUG: Clenbuterol hydrochloride, Clenbuterol )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 1 | Spinal and bulbar muscular atrophy | 3 |
| 2 | Amyotrophic lateral sclerosis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 113 | Muscular dystrophy | 1 |
| 256 | Muscle glycogenosis | 1 |
1. Spinal and bulbar muscular atrophy
Clinical trials : 19 / Drugs : 16 - (DrugBank : 7) / Drug target genes : 10 - Drug target pathways : 18
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
2. Amyotrophic lateral sclerosis
Clinical trials : 786 / Drugs : 550 - (DrugBank : 182) / Drug target genes : 170 - Drug target pathways : 232
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
113. Muscular dystrophy
Clinical trials : 766 / Drugs : 477 - (DrugBank : 119) / Drug target genes : 80 - Drug target pathways : 178
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
256. Muscle glycogenosis
Clinical trials : 193 / Drugs : 97 - (DrugBank : 28) / Drug target genes : 19 - Drug target pathways : 93
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
